复宏汉霖:HLX43三联疗法获NMPA批准开展临床试验

华尔街见闻
Jan 27

复宏汉霖HLX43三联疗法获批临床试验核心要点:获批情况:HLX43(靶向PD-L1抗体偶联药物)联合HLX07(抗EGFR单抗)及汉斯状(斯鲁利单抗)用于晚期实体瘤治疗的临床试验申请获NMPA批准,拟在中国境内开展。HLX43研发进展:在中国、美国、日本等多地开展1期/2期临床试验覆盖NSCLC、结直肠癌、宫颈癌、食管鳞癌等多个适应症临床数据显示:既往治疗失败的NSCLC患者ORR达37.0%,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10